Kwan Alan C, Tzolos Evangelos, Klein Eyal, Han Donghee, Lin Andrew, Kuronuma Keiichiro, Chen Billy, Flores Tomasino Guadalupe, Gransar Heidi, Slomka Piotr J, Cheng Susan, Gebhard Catherine, Kaufmann Philipp, Bax Jeroen J, Cademartiri Filippo, Chinnaiyan Kavitha, Chow Benjamin J W, Conte Edoardo, Cury Ricardo C, Feuchtner Gudrun, Hadamitzky Martin, Kim Yong-Jin, Leipsic Jonathon A, Maffei Erica, Marques Hugo, Plank Fabian, Pontone Gianluca, Villines Todd C, Al-Mallah Mouaz H, Gonçalves Pedro de Araújo, Danad Ibrahim, Lu Yao, Lee Ji-Hyun, Lee Sang-Eun, Baskaran Lohendran, Al'Aref Subhi J, Budoff Matthew J, Samady Habib, Stone Peter H, Virmani Renu, Achenbach Stephan, Narula Jagat, Chang Hyuk-Jae, Shaw Leslee J, Berman Daniel S, Lin Fay, Dey Damini
Departments of Imaging, Cardiology, Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, 116 N Robertson Blvd, Los Angeles, CA 90048.
Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland.
Radiol Cardiothorac Imaging. 2025 Jun;7(3):e240200. doi: 10.1148/ryct.240200.
Purpose Pericoronary adipose tissue attenuation (PCATa) measured at coronary CT angiography (CCTA) is an imaging biomarker of coronary inflammation associated with long-term adverse cardiac events. The authors hypothesized that PCATa may independently identify patients at risk for acute coronary syndromes (ACS). Materials and Methods The authors performed a retrospective substudy of the Incident Coronary Syndromes Identified by Computed Tomography (ICONIC) study, a propensity-matched case-control study of patients with CCTA followed by ACS. Two hundred analyzable case and control pairs were identified from the original 234 pairs. PCATa was measured using the adjusted attenuation of fat around proximal coronary vessels. The primary analysis applied conditional Cox models with cluster-robust standard errors to predict patient-level incident ACS, with adjustment for quantitative plaque volumes and clinical reporting-oriented findings of maximal stenosis and high-risk plaque features (HRPF). Results A total of 400 patients with 1174 matched measurable vessels were included. PCATa was not significantly different between patients with future ACS versus controls (-72.99 HU ± 9.42 vs -73.96 HU ± 9.47; = .08). Conversely, PCATa was significantly associated with incident ACS events in Cox models (adjusted for noncalcified plaque hazard ratio [HR]: 1.015; 95% CI: 1.001, 1.028; = .03; adjusted for total plaque HR: 1.015; 95% CI: 1.002, 1.029; = .03; adjusted for stenosis and HRPF HR: 1.014; 95% CI: 1.000, 1.028; = .049). Conclusion Limited quantitative difference in PCATa between patients and controls matched for risk factors and coronary artery disease suggests that PCATa may not be a useful single marker to identify future ACS. Nonetheless, significant differences seen in adjusted survival models identify a small biologic effect for increased risk of future ACS independent of traditional risk factors. CT-Angiography, Inflammation, Coronary Arteries, Acute Coronary Syndrome, Pericoronary Adipose Tissue Attenuation, Noncalcified Plaque, ICONIC Study, Cardiovascular Risk Clinical trials registration no. NCT02959099 © RSNA, 2025.
目的 在冠状动脉CT血管造影(CCTA)中测量的冠状动脉周围脂肪组织衰减(PCATa)是一种与长期不良心脏事件相关的冠状动脉炎症的成像生物标志物。作者推测PCATa可能独立识别急性冠状动脉综合征(ACS)风险患者。材料与方法 作者对计算机断层扫描识别的新发冠状动脉综合征(ICONIC)研究进行了一项回顾性子研究,这是一项对接受CCTA检查后发生ACS的患者进行倾向匹配的病例对照研究。从最初的234对中确定了200对可分析的病例和对照。使用近端冠状动脉血管周围脂肪的调整衰减来测量PCATa。主要分析应用具有聚类稳健标准误差的条件Cox模型来预测患者层面的新发ACS,并对定量斑块体积以及最大狭窄和高危斑块特征(HRPF)的临床报告导向性结果进行调整。结果 总共纳入了400例患者,共1174条匹配的可测量血管。未来发生ACS的患者与对照组之间的PCATa无显著差异(-72.99 HU±9.42 vs -73.96 HU±9.47;P = 0.08)。相反,在Cox模型中,PCATa与新发ACS事件显著相关(调整非钙化斑块风险比[HR]:1.015;95%CI:1.001,1.028;P = 0.03;调整总斑块HR:1.015;95%CI:1.002,1.029;P = 0.03;调整狭窄和HRPF HR:1.014;95%CI:1.000,1.028;P = 0.049)。结论 在根据风险因素和冠状动脉疾病进行匹配的患者与对照组之间,PCATa定量差异有限,这表明PCATa可能不是识别未来ACS的有用单一标志物。尽管如此,在调整后的生存模型中观察到的显著差异表明,独立于传统风险因素,PCATa对未来ACS风险增加有微小的生物学影响。CT血管造影、炎症、冠状动脉、急性冠状动脉综合征、冠状动脉周围脂肪组织衰减、非钙化斑块、ICONIC研究、心血管风险 临床试验注册号:NCT02959099 © RSNA,2025